1h Free Analyst Time
Speak directly to the analyst to clarify any post sales queries you may have.
The BRAF inhibitor market is entering a critical period, defined by a shift towards precision medicine, innovative drug combinations, and dynamic stakeholder engagement. Senior decision-makers face heightened complexity as regulatory, competitive, and supply chain factors evolve, making targeted insights essential for optimizing commercial strategy and clinical impact.
Market Snapshot: BRAF Inhibitor Landscape
The BRAF inhibitor market is witnessing a transformation driven by precision oncology, amplified by advancements in molecular diagnostics and targeted therapies. With the growing approval of combination regimens and increased adoption across melanoma, non-small cell lung carcinoma, and colorectal indications, the sector’s trajectory reflects robust growth potential. Integration of these therapies into clinical workflows highlights an industry-wide commitment to personalized medicine and improved survival outcomes.
Scope & Segmentation
This report delivers a comprehensive analysis of the BRAF inhibitor sector, covering a detailed segmentation and geographic breakdown essential for confident decision-making:
- Indications: Colorectal cancer, Lung cancer, Melanoma, with context-specific distinctions such as early-stage CRC, mCRC, NSCLC, SCLC, advanced melanoma, and metastatic melanoma.
- Drug Types: Dabrafenib, Encorafenib, Vemurafenib, each presenting unique mechanisms, safety profiles, and potential for combination with MEK inhibitors or immunotherapies.
- Distribution Channels: Hospital pharmacy (private/public), Online pharmacy, Retail pharmacy (chain/independent).
- End Users: Hospitals (general, specialty cancer centers), Specialist clinics (hospital outpatient, independent clinics).
- Therapy Lines: First line, Second line, enabling strategic positioning across various patient care pathways.
- Route of Administration: Oral formulations, supporting patient adherence and flexible dosing.
- Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including key countries such as United Kingdom, Germany, France, Russia, UAE, South Africa), and Asia-Pacific (China, India, Japan, Australia, South Korea, among others).
- Leading Companies Analysed: F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc.
Key Takeaways for Decision-Makers
- Next-generation BRAF inhibitor development prioritizes enhanced target selectivity and penetration into the central nervous system, addressing significant clinical challenges.
- Combination regimens with checkpoint inhibitors and MEK inhibitors expand therapeutic value, requiring robust real-world data to inform patient selection and long-term benefit.
- Regulatory agencies are accelerating approvals for high-impact therapies, prompting faster market entries and competitive innovation cycles.
- Strategic alliances and digital health investments support market differentiation and rapid scale-up, particularly in emerging and underserved regions.
- Diversified channel strategies—leveraging hospital networks, retail, and online pharmacies—increase access, while advanced analytics enable payers and providers to optimize resource allocation.
- Expanded molecular testing, championed by advocacy groups and professional societies, underpins growth by embedding BRAF screening in routine cancer diagnostics.
Tariff Impact: Navigating U.S. Policy Changes
New United States tariff measures, effective in 2025, are likely to impact BRAF inhibitor supply chains through increased manufacturing costs and potential pricing pressures. Pharmaceutical companies reliant on international sources for active pharmaceutical ingredients face rising import duties. Proactive responses, such as nearshoring production and renegotiating supplier agreements, are recommended to control costs and maintain competitive pricing structures. These tariff dynamics also highlight the importance of risk-sharing contracts and early policy engagement for uninterrupted patient access and business continuity.
BRAF Inhibitor Market: Methodology & Data Sources
This analysis employs a hybrid research approach that integrates primary interviews with oncologists, payers, and regulatory experts, alongside secondary reviews of literature, clinical trial registries, patent documents, and company disclosures. Scenario analysis and cross-validation ensure reliable, actionable intelligence for strategic planning.
BRAF Inhibitor Market: Why This Report Matters
- Enables informed portfolio decisions by clarifying nuanced market segments and regional access challenges.
- Delivers actionable intelligence on evolving regulatory conditions, emerging technologies, and competitive dynamics.
- Supports strategic planning around supply chain resilience, pricing, and product positioning in a high-growth sector.
Conclusion
The BRAF inhibitor market is marked by continual innovation, regulatory acceleration, and strategic adaptation. Effective execution will depend on tailored regional strategies and collaborative approaches that maximize clinical and commercial value, supporting improved patient outcomes and sustained growth.
This product will be delivered within 1-3 business days.
Table of Contents
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Expansion of BRAF inhibitor indications into nonmelanoma cancers driven by genomic profiling studies
5.2. Emergence of next generation BRAF inhibitors targeting resistance-associated mutations in clinical trials
5.3. Rising investment in biomarker-driven patient selection to optimize BRAF inhibitor therapy outcomes
5.4. Growing exploration of intermittent dosing schedules to manage toxicity and delay resistance in BRAF inhibitor regimens
5.5. Integration of real-world evidence studies assessing long-term survival benefits of BRAF inhibitor combinations
5.2. Emergence of next generation BRAF inhibitors targeting resistance-associated mutations in clinical trials
5.3. Rising investment in biomarker-driven patient selection to optimize BRAF inhibitor therapy outcomes
5.4. Growing exploration of intermittent dosing schedules to manage toxicity and delay resistance in BRAF inhibitor regimens
5.5. Integration of real-world evidence studies assessing long-term survival benefits of BRAF inhibitor combinations
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
6.2. PESTLE Analysis
8. BRAF Inhibitors Market, by Indication
8.1. Introduction
8.2. Colorectal Cancer
8.2.1. Early Stage Crc
8.2.2. Mcrc
8.3. Lung Cancer
8.3.1. Nsclc
8.3.2. Sclc
8.4. Melanoma
8.4.1. Advanced Melanoma
8.4.2. Metastatic Melanoma
8.2. Colorectal Cancer
8.2.1. Early Stage Crc
8.2.2. Mcrc
8.3. Lung Cancer
8.3.1. Nsclc
8.3.2. Sclc
8.4. Melanoma
8.4.1. Advanced Melanoma
8.4.2. Metastatic Melanoma
9. BRAF Inhibitors Market, by Drug Type
9.1. Introduction
9.2. Dabrafenib
9.3. Encorafenib
9.4. Vemurafenib
9.2. Dabrafenib
9.3. Encorafenib
9.4. Vemurafenib
10. BRAF Inhibitors Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.2.1. Private Hospital Pharmacy
10.2.2. Public Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
10.4.1. Chain Pharmacy
10.4.2. Independent Pharmacy
10.2. Hospital Pharmacy
10.2.1. Private Hospital Pharmacy
10.2.2. Public Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
10.4.1. Chain Pharmacy
10.4.2. Independent Pharmacy
11. BRAF Inhibitors Market, by End User
11.1. Introduction
11.2. Hospitals
11.2.1. General Hospitals
11.2.2. Specialty Cancer Centers
11.3. Specialist Clinics
11.3.1. Hospital Outpatient Clinics
11.3.2. Independent Clinics
11.2. Hospitals
11.2.1. General Hospitals
11.2.2. Specialty Cancer Centers
11.3. Specialist Clinics
11.3.1. Hospital Outpatient Clinics
11.3.2. Independent Clinics
12. BRAF Inhibitors Market, by Therapy Line
12.1. Introduction
12.2. First Line
12.3. Second Line
12.2. First Line
12.3. Second Line
13. BRAF Inhibitors Market, by Route of Administration
13.1. Introduction
13.2. Oral
13.2. Oral
14. Americas BRAF Inhibitors Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa BRAF Inhibitors Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific BRAF Inhibitors Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. F. Hoffmann-La Roche Ltd
17.3.2. Novartis AG
17.3.3. Pfizer Inc.
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. F. Hoffmann-La Roche Ltd
17.3.2. Novartis AG
17.3.3. Pfizer Inc.
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. BRAF INHIBITORS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL BRAF INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRAF INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRAF INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BRAF INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BRAF INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. BRAF INHIBITORS MARKET: RESEARCHAI
FIGURE 28. BRAF INHIBITORS MARKET: RESEARCHSTATISTICS
FIGURE 29. BRAF INHIBITORS MARKET: RESEARCHCONTACTS
FIGURE 30. BRAF INHIBITORS MARKET: RESEARCHARTICLES
FIGURE 2. GLOBAL BRAF INHIBITORS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BRAF INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BRAF INHIBITORS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. BRAF INHIBITORS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. BRAF INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. BRAF INHIBITORS MARKET: RESEARCHAI
FIGURE 28. BRAF INHIBITORS MARKET: RESEARCHSTATISTICS
FIGURE 29. BRAF INHIBITORS MARKET: RESEARCHCONTACTS
FIGURE 30. BRAF INHIBITORS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. BRAF INHIBITORS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRAF INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BRAF INHIBITORS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BRAF INHIBITORS MARKET SIZE, BY EARLY STAGE CRC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BRAF INHIBITORS MARKET SIZE, BY EARLY STAGE CRC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MCRC, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MCRC, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BRAF INHIBITORS MARKET SIZE, BY NSCLC, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BRAF INHIBITORS MARKET SIZE, BY NSCLC, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SCLC, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SCLC, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ADVANCED MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ADVANCED MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BRAF INHIBITORS MARKET SIZE, BY METASTATIC MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BRAF INHIBITORS MARKET SIZE, BY METASTATIC MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DABRAFENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DABRAFENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ENCORAFENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ENCORAFENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BRAF INHIBITORS MARKET SIZE, BY VEMURAFENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BRAF INHIBITORS MARKET SIZE, BY VEMURAFENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BRAF INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BRAF INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALTY CANCER CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALTY CANCER CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL OUTPATIENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL BRAF INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL BRAF INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 147. CANADA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. CANADA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. CANADA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 150. CANADA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 151. CANADA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 152. CANADA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 153. CANADA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 154. CANADA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 155. CANADA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 156. CANADA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 157. CANADA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. CANADA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. CANADA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 160. CANADA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 161. CANADA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 162. CANADA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 163. CANADA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. CANADA BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. CANADA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 166. CANADA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 167. CANADA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 168. CANADA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 169. CANADA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 170. CANADA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 171. CANADA BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. CANADA BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. MEXICO BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. MEXICO BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. MEXICO BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 176. MEXICO BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 177. MEXICO BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 178. MEXICO BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 179. MEXICO BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 180. MEXICO BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 181. MEXICO BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 182. MEXICO BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 183. MEXICO BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. MEXICO BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. MEXICO BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 186. MEXICO BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 187. MEXICO BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 188. MEXICO BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 189. MEXICO BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. MEXICO BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. MEXICO BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 192. MEXICO BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 193. MEXICO BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 194. MEXICO BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 195. MEXICO BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 196. MEXICO BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 197. MEXICO BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. MEXICO BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 305. GERMANY BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 306. GERMANY BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 307. GERMANY BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 308. GERMANY BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 309. GERMANY BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 310. GERMANY BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 311. GERMANY BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 312. GERMANY BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 313. GERMANY BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 314. GERMANY BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 315. GERMANY BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. GERMANY BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. GERMANY BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 318. GERMANY BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 319. GERMANY BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 320. GERMANY BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 321. GERMANY BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 322. GERMANY BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 323. GERMANY BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 324. GERMANY BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 325. GERMANY BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 326. GERMANY BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 327. GERMANY BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 328. GERMANY BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 329. GERMANY BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 330. GERMANY BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 331. FRANCE BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 332. FRANCE BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 333. FRANCE BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 334. FRANCE BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 335. FRANCE BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 336. FRANCE BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 337. FRANCE BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 338. FRANCE BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 339. FRANCE BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 340. FRANCE BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 341. FRANCE BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 342. FRANCE BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 343. FRANCE BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 344. FRANCE BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 345. FRANCE BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 346. FRANCE BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 347. FRANCE BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 348. FRANCE BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 349. FRANCE BRAF INHIBITORS MARKET
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BRAF INHIBITORS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL BRAF INHIBITORS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL BRAF INHIBITORS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL BRAF INHIBITORS MARKET SIZE, BY EARLY STAGE CRC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL BRAF INHIBITORS MARKET SIZE, BY EARLY STAGE CRC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MCRC, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MCRC, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL BRAF INHIBITORS MARKET SIZE, BY NSCLC, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL BRAF INHIBITORS MARKET SIZE, BY NSCLC, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SCLC, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SCLC, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ADVANCED MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ADVANCED MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL BRAF INHIBITORS MARKET SIZE, BY METASTATIC MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL BRAF INHIBITORS MARKET SIZE, BY METASTATIC MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DABRAFENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DABRAFENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ENCORAFENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ENCORAFENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL BRAF INHIBITORS MARKET SIZE, BY VEMURAFENIB, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL BRAF INHIBITORS MARKET SIZE, BY VEMURAFENIB, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PRIVATE HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL BRAF INHIBITORS MARKET SIZE, BY PUBLIC HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL BRAF INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL BRAF INHIBITORS MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL BRAF INHIBITORS MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALTY CANCER CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALTY CANCER CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL OUTPATIENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL OUTPATIENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL BRAF INHIBITORS MARKET SIZE, BY INDEPENDENT CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL BRAF INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL BRAF INHIBITORS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL BRAF INHIBITORS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL BRAF INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES BRAF INHIBITORS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 147. CANADA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. CANADA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. CANADA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 150. CANADA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 151. CANADA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 152. CANADA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 153. CANADA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 154. CANADA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 155. CANADA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 156. CANADA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 157. CANADA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. CANADA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. CANADA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 160. CANADA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 161. CANADA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 162. CANADA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 163. CANADA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. CANADA BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. CANADA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 166. CANADA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 167. CANADA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 168. CANADA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 169. CANADA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 170. CANADA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 171. CANADA BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 172. CANADA BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 173. MEXICO BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 174. MEXICO BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 175. MEXICO BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 176. MEXICO BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 177. MEXICO BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 178. MEXICO BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 179. MEXICO BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 180. MEXICO BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 181. MEXICO BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 182. MEXICO BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 183. MEXICO BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 184. MEXICO BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 185. MEXICO BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 186. MEXICO BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 187. MEXICO BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 188. MEXICO BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 189. MEXICO BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. MEXICO BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. MEXICO BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 192. MEXICO BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 193. MEXICO BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 194. MEXICO BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 195. MEXICO BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 196. MEXICO BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 197. MEXICO BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. MEXICO BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 203. BRAZIL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 204. BRAZIL BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 205. BRAZIL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 206. BRAZIL BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 207. BRAZIL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 208. BRAZIL BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 225. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 226. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 227. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 228. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 229. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 230. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 231. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 232. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 233. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 234. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 251. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 252. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 253. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 254. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 255. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 256. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 257. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 258. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 259. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 260. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA BRAF INHIBITORS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 280. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 282. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 284. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 285. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 286. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 287. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 288. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 305. GERMANY BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 306. GERMANY BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 307. GERMANY BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 308. GERMANY BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 309. GERMANY BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 310. GERMANY BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 311. GERMANY BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 312. GERMANY BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 313. GERMANY BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 314. GERMANY BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 315. GERMANY BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 316. GERMANY BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 317. GERMANY BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 318. GERMANY BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 319. GERMANY BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 320. GERMANY BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 321. GERMANY BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 322. GERMANY BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 323. GERMANY BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 324. GERMANY BRAF INHIBITORS MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 325. GERMANY BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 326. GERMANY BRAF INHIBITORS MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 327. GERMANY BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 328. GERMANY BRAF INHIBITORS MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 329. GERMANY BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 330. GERMANY BRAF INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 331. FRANCE BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 332. FRANCE BRAF INHIBITORS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 333. FRANCE BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2018-2024 (USD MILLION)
TABLE 334. FRANCE BRAF INHIBITORS MARKET SIZE, BY COLORECTAL CANCER, 2025-2030 (USD MILLION)
TABLE 335. FRANCE BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 336. FRANCE BRAF INHIBITORS MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 337. FRANCE BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 338. FRANCE BRAF INHIBITORS MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 339. FRANCE BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
TABLE 340. FRANCE BRAF INHIBITORS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
TABLE 341. FRANCE BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 342. FRANCE BRAF INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 343. FRANCE BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2024 (USD MILLION)
TABLE 344. FRANCE BRAF INHIBITORS MARKET SIZE, BY HOSPITAL PHARMACY, 2025-2030 (USD MILLION)
TABLE 345. FRANCE BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2018-2024 (USD MILLION)
TABLE 346. FRANCE BRAF INHIBITORS MARKET SIZE, BY RETAIL PHARMACY, 2025-2030 (USD MILLION)
TABLE 347. FRANCE BRAF INHIBITORS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 348. FRANCE BRAF INHIBITORS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 349. FRANCE BRAF INHIBITORS MARKET
Samples
LOADING...
Companies Mentioned
The companies profiled in this BRAF Inhibitors market report include:- F. Hoffmann-La Roche Ltd
- Novartis AG
- Pfizer Inc.
